|
1
|
Arbyn M, Weiderpass E, Bruni L, de Sanjosé
S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and
mortality of cervical cancer in 2018: A worldwide analysis. Lancet
Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brisson M and Drolet M: Global elimination
of cervical cancer as a public health problem. Lancet Oncol.
20:319–321. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Simms KT, Steinberg J, Caruana M, Smith
MA, Lew JB, Soerjomataram I, Castle PE, Bray F and Canfell K:
Impact of scaled up human papillomavirus vaccination and cervical
screening and the potential for global elimination of cervical
cancer in 181 countries, 2020-99: A modelling study. Lancet Oncol.
20:394–407. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin C, Slama J, Gonzalez P, Goodman MT,
Xia N, Kreimer AR, Wu T, Hessol NA, Shvetsov Y, Ortiz AP, et al:
Cervical determinants of anal HPV infection and high-grade anal
lesions in women: A collaborative pooled analysis. Lancet Infect
Dis. 19:880–891. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang J, Cai H, Xiao ZX, Wang H and Yang P:
Effect of radiotherapy on the survival of cervical cancer patients:
An analysis based on SEER database. Medicine (Baltimore).
98:e164212019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu Y, Zhou Y, Qu W, Deng M and Zhang C: A
Lasso regression model for the construction of microRNA-target
regulatory networks. Bioinformatics. 27:2406–2413. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao C, Sun D, Zhang L and Song L: miR-186
affects the proliferation, invasion and migration of human gastric
cancer by inhibition of Twist1. Oncotarget. 7:79956–79963. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong S, Wang R, Wang H, Ding Q, Zhou X,
Wang J, Zhang K, Long Y, Lu S, Hong T, et al: HOXD-AS1 promotes the
epithelial to mesenchymal transition of ovarian cancer cells by
regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res.
38:1102019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Z, Zhang G, Yu W, Gao N and Peng J:
miR-186 inhibits cell proliferation in multiple myeloma by
repressing Jagged1. Biochem Biophys Res Commun. 469:692–697. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su BB, Zhou SW, Gan CB and Zhang XN:
miR-186 inhibits cell proliferation and invasion in human cutaneous
malignant melanoma. J Cancer Res Ther. 14 (Suppl):S60–S64. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qiu H, Yuan S and Lu X: miR-186 suppressed
CYLD expression and promoted cell proliferation in human melanoma.
Oncol Lett. 12:2301–2306. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu L, Wang Y, Bai R, Yang K and Tian Z:
miR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α
regulation. Oncogenesis. 5:e2242016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yao K, He L, Gan Y, Zeng Q, Dai Y and Tan
J: miR-186 suppresses the growth and metastasis of bladder cancer
by targeting NSBP1. Diagn Pathol. 10:1462015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang R, Bao H, Zhang S, Li R, Chen L and
Zhu Y: miR-186-5p Promotes Apoptosis by Targeting IGF-1 in SH-SY5Y
OGD/R Model. Int J Biol Sci. 14:1791–1799. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He M, Jin Q, Chen C, Liu Y, Ye X, Jiang Y,
Ji F, Qian H, Gan D, Yue S, et al: The miR-186-3p/EREG axis
orchestrates tamoxifen resistance and aerobic glycolysis in breast
cancer cells. Oncogene. 38:5551–5565. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Honegger A, Schilling D, Bastian S,
Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K and
Hoppe-Seyler F: Dependence of intracellular and exosomal microRNAs
on viral E6/E7 oncogene expression in HPV-positive tumor cells.
PLoS Pathog. 11:e10047122015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu C, Wang J, Hu Y, Xie H, Liu M and Tang
H: Upregulation of kazrin F by miR-186 suppresses apoptosis but
promotes epithelial-mesenchymal transition to contribute to
malignancy in human cervical cancer cells. Chin J Cancer Res.
29:45–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang JJ, Wang DD, Du CX and Wang Y: Long
Noncoding RNA ANRIL Promotes Cervical Cancer Development by Acting
as a Sponge of miR-186. Oncol Res. 26:345–352. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kucherlapati M: Examining transcriptional
changes to DNA replication and repair factors over uveal melanoma
subtypes. BMC Cancer. 18:8182018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lei M, Kawasaki Y, Young MR, Kihara M,
Sugino A and Tye BK: Mcm2 is a target of regulation by Cdc7-Dbf4
during the initiation of DNA synthesis. Genes Dev. 11:3365–3374.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Issac MSM, Yousef E, Tahir MR and Gaboury
LA: MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in
Diagnosis and Prognosis. Neoplasia. 21:1015–1035. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gad SA, Ali HEA, Gaballa R, Abdelsalam RM,
Zerfaoui M, Ali HI, Salama SH, Kenawy SA, Kandil E and Abd Elmageed
ZY: Targeting CDC7 sensitizes resistance melanoma cells to
BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway.
Sci Rep. 9:141972019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aihemaiti G, Kurata M, Nogawa D, Yamamoto
A, Mineo T, Onishi I, Kinowaki Y, Jin XH, Tatsuzawa A, Miyasaka N,
et al: Subcellular localization of MCM2 correlates with the
prognosis of ovarian clear cell carcinoma. Oncotarget.
9:28213–28225. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Al-Hazmi N, Alhazzazi T, Williams G,
Stoeber K and Al-Dabbagh R: DNA replication licensing factor MCM2,
geminin, and Ki67 define proliferative state and are linked with
survival in oral squamous cell carcinoma. Eur J Oral Sci.
126:186–196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kaur G, Balasubramaniam SD, Lee YJ,
Balakrishnan V and Oon CE: Minichromosome Maintenance Complex (MCM)
Genes Profiling and MCM2 Protein Expression in Cervical Cancer
Development. Asian Pac J Cancer Prev. 20:3043–3049. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang X, Xu Y, Lu L, Jiao Y, Liu J, Wang L
and Zhao H: Identification of key candidate genes and small
molecule drugs in cervical cancer by bioinformatics strategy.
Cancer Manag Res. 10:3533–3549. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amaro Filho SM, Nuovo GJ, Cunha CB, Ramos
Pereira LO, Oliveira-Silva M, Russomano F, Pires A and Nicol AF:
Correlation of MCM2 detection with stage and virology of cervical
cancer. Int J Biol Markers. 29:e363–e371. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu Z, Zhou Y, Shi F, Cao Y, Dinh TLA, Wan
J and Zhao M: Investigation of differentially-expressed microRNAs
and genes in cervical cancer using an integrated bioinformatics
analysis. Oncol Lett. 13:2784–2790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ,
Trimble CL, Fearon ER and Cho KR: Gene expression analysis of
preinvasive and invasive cervical squamous cell carcinomas
identifies HOXC10 as a key mediator of invasion. Cancer Res.
67:10163–10172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
den Boon JA, Pyeon D, Wang SS, Horswill M,
Schiffman M, Sherman M, Zuna RE, Wang Z, Hewitt SM, Pearson R, et
al: Molecular transitions from papillomavirus infection to cervical
precancer and cancer: Role of stromal estrogen receptor signaling.
Proc Natl Acad Sci USA. 112:E3255–E3264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Matsuo K, Machida H, Mandelbaum RS,
Konishi I and Mikami M: Validation of the 2018 FIGO cervical cancer
staging system. Gynecol Oncol. 152:87–93. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Powazniak Y, Kempfer AC, Pereyra JC,
Palomino JP and Lazzari MA: VWF and ADAMTS13 behavior in
estradiol-treated HUVEC. Eur J Haematol. 86:140–147. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zheng J: Diagnostic value of MCM2
immunocytochemical staining in cervical lesions and its
relationship with HPV infection. Int J Clin Exp Pathol. 8:875–880.
2015.PubMed/NCBI
|
|
36
|
Smith RA, Manassaram-Baptiste D, Brooks D,
Doroshenk M, Fedewa S, Saslow D, Brawley OW and Wender R: Cancer
screening in the United States, 2015: A review of current American
cancer society guidelines and current issues in cancer screening.
CA Cancer J Clin. 65:30–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brisson M, Kim JJ, Canfell K, Drolet M,
Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily MC, et
al: Impact of HPV vaccination and cervical screening on cervical
cancer elimination: A comparative modelling analysis in 78
low-income and lower-middle-income countries. Lancet. 395:575–590.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Petroni G, Formenti SC, Chen-Kiang S and
Galluzzi L: Immunomodulation by anticancer cell cycle inhibitors.
Nat Rev Immunol. 20:669–679. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Romero-Pozuelo J, Figlia G, Kaya O,
Martin-Villalba A and Teleman AA: Cdk4 and Cdk6 Couple the
Cell-Cycle Machinery to Cell Growth via mTORC1. Cell Rep.
31:1075042020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qie S, Yoshida A, Parnham S, Oleinik N,
Beeson GC, Beeson CC, Ogretmen B, Bass AJ, Wong KK, Rustgi AK, et
al: Targeting glutamine-addiction and overcoming CDK4/6 inhibitor
resistance in human esophageal squamous cell carcinoma. Nat Commun.
10:12962019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Whittle JR, Vaillant F, Surgenor E,
Policheni AN, Giner G, Capaldo BD, Chen HR, Liu HK, Dekkers JF,
Sachs N, et al: Dual Targeting of CDK4/6 and BCL2 Pathways Augments
Tumor Response in Estrogen Receptor-Positive Breast Cancer. Clin
Cancer Res. 26:4120–4134. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schmoellerl J, Barbosa IAM, Eder T,
Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT,
Sagarajit M, Ebner J, et al: CDK6 is an essential direct target of
NUP98 fusion proteins in acute myeloid leukemia. Blood.
136:387–400. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu X, Song J, Zhang Y, Wang H, Sun H,
Feng X, Hou M, Chen G, Tang Q and Ji M: ASF1B promotes cervical
cancer progression through stabilization of CDK9. Cell Death Dis.
11:7052020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee S, Ho JY, Liu JJ, Lee H, Park JY, Baik
M, Ko M, Lee SU, Choi YJ and Hur SY: CKD-602, a topoisomerase I
inhibitor, induces apoptosis and cell-cycle arrest and inhibits
invasion in cervical cancer. Mol Med. 25:232019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shen Z, Song W, Qian L, Zhu J, Li Y, Li M,
Zhang T, Zhao W, Zhou Y and Yang X: Effect of claudin 1 on cell
proliferation, migration and apoptosis in human cervical squamous
cell carcinoma. Oncol Rep. 45:606–618. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Forsburg SL: Eukaryotic MCM proteins:
Beyond replication initiation. Microbiol Mol Biol Rev. 68:109–131.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roupret M, Gontero P, McCracken SRC,
Dudderidge T, Stockley J, Kennedy A, Rodriguez O, Sieverink C,
Vanié F, Allasia M, et al: Diagnostic Accuracy of MCM5 for the
Detection of Recurrence in Nonmuscle Invasive Bladder Cancer
Followup: A Blinded, Prospective Cohort, Multicenter European
Study. J Urol. 204:685–690. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhao Y, Wang Y, Zhu F, Zhang J, Ma X and
Zhang D: Gene expression profiling revealed MCM3 to be a better
marker than Ki67 in prognosis of invasive ductal breast carcinoma
patients. Clin Exp Med. 20:249–259. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rachagani S, Macha MA, Heimann N,
Seshacharyulu P, Haridas D, Chugh S and Batra SK: Clinical
implications of miRNAs in the pathogenesis, diagnosis and therapy
of pancreatic cancer. Adv Drug Deliv Rev. 81:16–33. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Garofalo M and Croce CM: Role of microRNAs
in maintaining cancer stem cells. Adv Drug Deliv Rev. 81:53–61.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang R, Wei M, Yang F, Sheng Y and Ji L:
Diosbulbin B induced G2/M cell cycle arrest in hepatocytes by
miRNA-186-3p and miRNA-378a-5p-mediated the decreased expression of
CDK1. Toxicol Appl Pharmacol. 357:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu Y, Guo R, Qiao Y, Han L and Liu M:
LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical
cancer through NNT-AS1/miR-186/HMGB1 axis. Cancer Cell Int.
20:1902020. View Article : Google Scholar : PubMed/NCBI
|
